MG-132

MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

Price Stock Quantity  
In DMSO USD 100 In stock
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MG-132 Chemical Structure

MG-132 Chemical Structure
Molecular Weight: 475.62

Validation & Quality Control

Product Use Citation(40)

Customer Product Validation(9)

Quality Control & MSDS

Related Compound Libraries

MG-132 is available in the following compound libraries:

Proteasome Inhibitors with Unique Features

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.
Targets Proteasome [1]
(Cell-free assay)
IC50 100 nM
In vitro MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity Description
LPS-stimulated RAW264.7 cellsNUjiR4liTnWwY4Tpc44hSXO|YYm=MVqyOUDPxE1?NV3XN49WTE2VTx?=M2mxeGlvcGmkaYTzJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjFizszN
HL-60M1;xO2N6fG:2b4jpZ{BCe3OjeR?=NXvEdVNGPDBizszNMYC0PEBpNH74cphFVVORMln5TWM2ODxzMDFOwG0>
SMMC-7721NYjjZ3JiS3m2b4TvfIlkKEG|c3H5NIW5SHI1OCEQvF2=M{XDVFQ5KGh?MnP0SG1UVw>?MoHUTWM2OD15LkGg{txO
A-549NVHXOo5oS3m2b4TvfIlkKEG|c3H5MVO0NEDPxE1?MVe0PEBpMlPYSG1UVw>?NEnZZYNKSzVyPEGwJO69VQ>?
MCF-7NXHofW96S3m2b4TvfIlkKEG|c3H5NYXjNG9qPDBizszNNV;JWlVSPDhiaB?=M2X5RmROW09?NXXNPVFiUUN3ME23MlMh|ryP
SW-480M3S4SGN6fG:2b4jpZ{BCe3OjeR?=M2LiOFQxKM7:TR?=NIDhWmI1QCCqMoTKSG1UVw>?M2nzXWlEPTB;NDFOwG0>
NCI-H929MmqwR5l1d3SxeHnjJGF{e2G7M3jhblEh|ryPMonTO|IhcA>?NYjadVhETE2VTx?=MWDJR|UxRTBwMUeg{txO
293TNVPzTGdlS3m2b4TvfIlkKEG|c3H5MWWxNEDPxE1?MXO3NkBpNVLEN2J5TE2VTx?=NYL0[GN[UUN3MEyyJO69VQ>?
293TNH;wepZHfW6ldHnvckBCe3OjeR?=Mly3NVAh|ryPMWKyOEBpMnTvSG1UVw>?Mmj0UY9l\XKjdHXsfUBqdmS3Y3XzJIhm[XRvc3jvZ4shKA>?
HeLaNV3YUYRKU2mwYYPlJGF{e2G7MUOxNEDPxE1?M3X0RlEhcA>?MX;EUXNQMXrJcoR2[2W|IGDBVnAh[2ynYY\h[4Uh[nliaX7obYJqfGmwZzDwdo9{\WG|b33lJIFkfGm4aYT5
MDA-MB-231MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\xNUDPxE1?M2TK[VczKGh?MX7EUXNQNIjyZZpKSzVyPUCuNVgh|ryP
MCF-7MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XLdFEh|ryPM2rxe|czKGh?NHjpc2JFVVORNGjQ[WdKSzVyPUCuNVMh|ryP
MCF10AMnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXmxJO69VQ>?NHezR5Y4OiCqM{nVWWROW09?MljXTWM2OD1yLkK5JO69VQ>?
HEK-293M2PBdGtqdmG|ZTDBd5NigQ>?NUnObI5DOiCjbnSgNlAh|ryPNFjNU2kzKGh?MX3EUXNQMVTJcohq[mm2czDDbHQuVCCjY4Tpeol1gSC5aYToJGlEPTBib3[gPUBvVSB?
Calu6MU\GeY5kfGmxbjDBd5NigQ>?NGnmU28yOCEQvF2=NFT4NpcyQCCqM37sXGROW09?NUPHUZBTW2mpbnnmbYNidnSueTDhZ4N2dXWuYYTld{BnemG2YYjpckBxemWldYLzc5I>
IFN-gamma-induced RAW264.7M4TLWWZ2dmO2aX;uJGF{e2G7NY\2W2Z4TE2VTx?=NYTB[Y5RUW6qaXLpeJMhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDBwMEe3JO69VQ>?
IPC227FMkPsR5l1d3SxeHnjJGF{e2G7NHXOdpMyKM7:TR?=M4f2VVQ5KGh?NXPiNoxGTE2VTx?=MmjrTWM2OD1yLkC3O{DPxE1?
Hepa-1c1c7NXPlSmhITnWwY4Tpc44hSXO|YYm=M4CwZ|I2KM7:TR?=NYTsfnN4PiCqM1PBTmROW09?NV3IV2tuUW6lcnXhd4V{KE6{ZkKgdJJwfGWrbjDs[ZZmdA>?
COS-7M3PqV2N6fG:2b4jpZ{BCe3OjeR?=NFXuW5MyOCEQvF2=MmG5SG1UVw>?NVjZRmN4UUN3MEyxNEDPxE1?
HuH-7Ml;MR5l1d3SxeHnjJGF{e2G7M{jtd|ExKM7:TR?=M4rvUGROW09?NWTKPZh4UUN3MEyxNEDPxE1?
OCI-Ly3MYHGeY5kfGmxbjDBd5NigQ>?MW[xNEDPxE4EoB?=MoPzOEBpNFnPRnlFVVORNEfzN|BKdmS3Y3XzJIh2dWGwIFnrZZBx[UKjbIDoZUB{fGGkaXzpfoF1cW:wIIfpeIghTUN3MDDv[kAyKM7:TR?=
A2780 cDDPMnrKRZBweHSxc3nzJGF{e2G7M3fXeFI1KGh?Mm\uSG1UVw>?NU\vW2hUUW6mdXPld{BieG:ydH;zbZMh[nliaX7obYJqfGmwZzDQWGVPKGSnZ4Lh[IF1cW:w
LPS-stimulated RAW264.7 cellsMoHhSpVv[3Srb36gRZN{[Xl?M2TScmROW09?MkHoTY5pcWKrdIOgUmYuc2GycHHCJGRPSSCkaX7kbY5o
PC12NVj0TmpsTnWwY4Tpc44hSXO|YYm=M4LsfVExOCEQvF5CpC=>MkPiNlQhcA>?M{XzVmROW09?MYTJcohq[mm2czC2MW9JTEFvIHHu[EBJOk9{LXnu[JVk\WRiY4n0c5RwgGmlaYT5
PC3M3\Lbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF31[lgzOCEQvF2=NWXUOGNPPDhiaB?=NXS4PZg6TE2VTx?=M3HwemlEPTB;MD62JO69VQ>?
LP-1MkDrRZBweHSxc3nzJGF{e2G7NYHJbXpkOzByIH7NMUWyOEBpNFSw[3VFVVORMlTmTY5lfWOnczDhdI9xfG:|aYOgZpkhcW6lcnXhd4lv\yClbHXheoVlKFCDUmCgcIV3\WxiYX7kJJJm\HWlaX7nJG1kdC1zIIDyc5RmcW5ibHX2[Yw>
ES6MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIj4blVKSzVyPUCuNFE{ODZizszN
A101DMkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3r2NWlEPTB;MD6wN|I4QSEQvF2=
OCUB-MNWrLOnBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDBdIFKSzVyPUCuNFM4OzdizszN
LB2518-MELMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvtRVZ6UUN3ME2wMlA{PzZizszN
SH-4NUL3OGdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTTTWM2OD1yLkC0N|Eh|ryP
KNS-42MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTBwMES0OFEh|ryP
DSH1NHXFVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETCN4FKSzVyPUCuNFUzQDlizszN
NTERA-S-cl-D1M4LMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjJfHFjUUN3ME2wMlA2Pzd{IN88US=>
D-542MGMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlu5TWM2OD1yLkC1PVU4KM7:TR?=
KS-1MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTBwME[0OVgh|ryP
BL-41MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTBwME[5OFch|ryP
LXF-289M4HWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M16ycmlEPTB;MD6wO|A3PiEQvF2=
D-247MGNX\3V2V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHqwTYJKSzVyPUCuNFczODlizszN
MMAC-SFM1zxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\LVmRKSzVyPUCuNFczPjhizszN
CP66-MELMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTBwMEe1JO69VQ>?
LB771-HNCNWP3b41KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjOWYpvUUN3ME2wMlA5ODN4IN88US=>
no-10Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHOW2s1UUN3ME2wMlA5QTB7IN88US=>
A388MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37RZ2lEPTB;MD6wPVA3PSEQvF2=
OPM-2NVPiN3lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnaTpNZUUN3ME2wMlExPDd2IN88US=>
OVCAR-4MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTBwMUC5N|gh|ryP
HOP-62NIiwVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHNVY4xUUN3ME2wMlExQTR7IN88US=>
ML-2M2XZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXW1TIw1UUN3ME2wMlEyQDB4IN88US=>
UACC-257MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\XVHVWUUN3ME2wMlEyQTJ5IN88US=>
NEC8MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHrcZhKSzVyPUCuNVE6QTVizszN
ONS-76NWfPOYxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTBwMUK5N|Uh|ryP
KE-37NIHzPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHu0b|hKSzVyPUCuNVMzPzhizszN
HT-144NVfjcZlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7TUVVTUUN3ME2wMlE{QDl3IN88US=>
LB2241-RCCMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPNb2JKSzVyPUCuNVQzPDdizszN
TE-5M2i2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTBwMUSyO|gh|ryP
KINGS-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{j1OWlEPTB;MD6xOFc6KM7:TR?=
NCI-H69NFrwXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHP5WItKSzVyPUCuNVUyPDFizszN
CAS-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3jTWM2OD1yLkG1OFgzKM7:TR?=
D-263MGMmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnWzTWM2OD1yLkG2NFA3KM7:TR?=
A253MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTBwMU[xNlgh|ryP
PF-382NX3RdWIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXWUmF6UUN3ME2wMlE3PzB4IN88US=>
CESSNGS5cnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjheJpKUUN3ME2wMlE4ODZizszN
MZ2-MELNX7pSWJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLOTWM2OD1yLkG3OVU6KM7:TR?=
HELNV2wdlJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH23cG1KSzVyPUCuNVg2OTdizszN
D-392MGNUHMSYpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIf3OVVKSzVyPUCuNVkyOTVizszN
SK-LMS-1Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1z2XWlEPTB;MD6xPVMxOyEQvF2=
GI-ME-NMkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\FTGlEPTB;MD6xPVMxPiEQvF2=
LB831-BLCM2XlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTBwMUmzOEDPxE1?
DU-4475MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFz0TGVKSzVyPUCuNVk3PThizszN
IST-SL1NUixNWx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjKUmRKSzVyPUCuNlAxQTRizszN
GAKMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3H6ZWlEPTB;MD6yNFU{PCEQvF2=
EW-1NIfiXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjXTWM2OD1yLkKxNFQ4KM7:TR?=
LAMA-84NVTrN4tYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPSTWM2OD1yLkKxPFUyKM7:TR?=
SK-UT-1M{noOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH[wTJZKSzVyPUCuNlIxPDlizszN
VA-ES-BJNXLET|hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\Rd2lEPTB;MD6yNlI2PyEQvF2=
ACNMmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEH5R4VKSzVyPUCuNlI3OzhizszN
SK-PN-DWNH;t[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnmTWM2OD1yLkKzNVkh|ryP
HD-MY-ZNIWwVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTaTWM2OD1yLkKzN|A{KM7:TR?=
LB373-MEL-DMoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjCZ3NKSzVyPUCuNlQyQThizszN
COLO-829NWDZZYk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfwOpRwUUN3ME2wMlI1OjV5IN88US=>
ES8NXm1OZRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTBwMkS3OlMh|ryP
RXF393M2rzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTBwMkWwNVUh|ryP
TK10Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILIT5pKSzVyPUCuNlU1OzVizszN
LOUCYM1Lz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlm4TWM2OD1yLkK1OFU3KM7:TR?=
MZ7-melM{LEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUe0boRUUUN3ME2wMlI3Ozd2IN88US=>
CP67-MELM3\seGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TJXGlEPTB;MD6yOlc{KM7:TR?=
C2BBe1Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TUVWlEPTB;MD6yO|kxPyEQvF2=
K052M3SwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\JTmlEPTB;MD6yPFk6KM7:TR?=
MOLT-16Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTBwMkm1NlQh|ryP
KNS-81-FDNVrZfo5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfhOGxKSzVyPUCuN|A{OjNizszN
CMKMmDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4WzN2lEPTB;MD6zNVEzKM7:TR?=
LAN-6Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\keWhOUUN3ME2wMlMyOyEQvF2=
KLENILXTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PDRmlEPTB;MD6zNVMxPiEQvF2=
NCCITM3;iOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfjTWM2OD1yLkOxO|g{KM7:TR?=
HHNFfsNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnq2TWM2OD1yLkOyPFk4KM7:TR?=
TE-8MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPlTWM2OD1yLkO0Nlc6KM7:TR?=
GDM-1NF3RT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlP3TWM2OD1yLkO1NVA1KM7:TR?=
NCI-H747NEfBUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1Tub2lEPTB;MD6zO|ExOyEQvF2=
NCI-H1092NUCwcJpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVv3cFFEUUN3ME2wMlM5QDR2IN88US=>
8-MG-BAMmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmX0TWM2OD1yLkO5PFM4KM7:TR?=
NB17MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PsTWlEPTB;MD60Nlk4KM7:TR?=
LC4-1NEnBO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mny3TWM2OD1yLkSzOlA4KM7:TR?=
TE-1M2\hb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTBwNEWxNVkh|ryP
KALS-1NUnETYN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DvWmlEPTB;MD60OlU5PCEQvF2=
CCRF-CEMNXXlTWhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\PTWM2OD1yLkS3Olc1KM7:TR?=
OS-RC-2NVvEWY1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTBwNEe5O|Ih|ryP
A704MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTBwNEi2PVIh|ryP
BB49-HNCMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml:2TWM2OD1yLkS5NFk3KM7:TR?=
EVSA-TNHj5c3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTBwNEm5NVEh|ryP
Mo-TM1nxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzOXHFSUUN3ME2wMlUyPzZ{IN88US=>
MONO-MAC-6NGP2dlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTDVo13UUN3ME2wMlU{PjFzIN88US=>
BB65-RCCNGHNR2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojRTWM2OD1yLkW2PFEyKM7:TR?=
NCI-H1882NUntUXlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTBwNUmwN|Yh|ryP
TE-9M2DmS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\tOFNKSzVyPUCuOlExOzNizszN
NCI-H2126NWnndpI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\rSVJCUUN3ME2wMlYzPjZ7IN88US=>
SF268MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\ybVJZUUN3ME2wMlY2PjRzIN88US=>
SW872NXnONW0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHYNo9KSzVyPUCuOlU4OjlizszN
LS-513NFfSTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjxcFN4UUN3ME2wMlY3PzVzIN88US=>
NCI-H1355NXXnfWtWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTBwNki2NVkh|ryP
BL-70MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTBwNkmzPFgh|ryP
NCI-SNU-5MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTBwNkm1OFUh|ryP
SNU-C2BNXLqdolKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTBwN{C3N|kh|ryP
GB-1NUO5ZXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33JeWlEPTB;MD63NlEzPCEQvF2=
CTB-1NEDMToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPDTWM2OD1yLke3PVU2KM7:TR?=
BeckerNYCwfJBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7o[pByUUN3ME2wMlc6PjJzIN88US=>
KM12M2e0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTBwOEW0OlYh|ryP
ES7NF32NFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTBwOEm2OUDPxE1?
COLO-684NUjjWVlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PyS2lEPTB;MD65NFY2QCEQvF2=
HCC2998NFzGPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPERlA1UUN3ME2wMlk{QDV2IN88US=>
TE-10NXvPUW04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHYWGJ7UUN3ME2wMlk3PDNizszN
SF126MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVqyV3NnUUN3ME2wMlk5QTdzIN88US=>
EKVXNXzVZoFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{L0XWlEPTB;MT6wN|Q1OiEQvF2=
KARPAS-45M4K2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7KO4xLUUN3ME2xMlA1ODF4IN88US=>
KGNMknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LFW2lEPTB;MT6wOVA1PSEQvF2=
ES1NF24VIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTFwMEe5NlEh|ryP
L-540Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7KTWM2OD1zLkGxPFM6KM7:TR?=
KURAMOCHIMon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTFwMUKzO|Qh|ryP
LU-65Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3pbYM4UUN3ME2xMlEzPzV|IN88US=>
MFH-inoNIDtfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7PTWM2OD1zLkG3OVAyKM7:TR?=
NCI-H23MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHOendKSzVyPUGuNlA1OSEQvF2=
IA-LMM4rvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PlOmlEPTB;MT6yOFEyPiEQvF2=
PSN1MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jt[mlEPTB;MT6yO|AyPiEQvF2=
NCI-H719NXHRTGJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3r3VGlEPTB;MT6yO|QyOSEQvF2=
SW684Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXUTWM2OD1zLkK4OlU6KM7:TR?=
HCE-4NIPDOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTyUoVXUUN3ME2xMlMxOjJzIN88US=>
EW-16NF6z[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfjTWM2OD1zLkOxN|Q4KM7:TR?=
NCI-H128MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzSe5hKSzVyPUGuN|U5OTRizszN
HC-1NI\yTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\lRZRKSzVyPUGuN|gyPyEQvF2=
IST-MES1NVHwXJdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPyWGxKSzVyPUGuOFAzODhizszN
RajiMmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTFwNEG4OUDPxE1?
DMS-114NEjGVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3M[HZKSzVyPUGuOFQ2OzlizszN
GI-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWi2NopIUUN3ME2xMlQ4OTNzIN88US=>
NCI-H2081M1ntV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rz[2lEPTB;MT61OVE6PiEQvF2=
LC-1FMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHn[GZZUUN3ME2xMlU2OTl6IN88US=>
NCI-H2227NWfUeGxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4j6cWlEPTB;MT62NVU3OSEQvF2=
D-502MGMl62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{ft[mlEPTB;MT62O|IyOSEQvF2=
NCI-H2141M33NbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTFwNkezNVch|ryP
LS-411NNGLzVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTFwNkm4NFch|ryP
SU-DHL-1M2jXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfyZXhKSzVyPUGuO|EzQDFizszN
BB30-HNCM4PXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvBdlVnUUN3ME2xMlczPjh3IN88US=>
TE-15M3HUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfYTWM2OD1zLkmyN|c{KM7:TR?=
JVM-3M2XlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXCdGxKSzVyPUGuPVM6ODRizszN
IST-SL2NFniZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjKTWM2OD1{LkCxNlUzKM7:TR?=
EW-18MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1:1V2lEPTB;Mj6wNlM{PyEQvF2=
DJM-1NXH6PIU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3vWVZ7UUN3ME2yMlAzPTV{IN88US=>
no-11MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXBOWJOUUN3ME2yMlA{OTB2IN88US=>
QIMR-WILNIrkVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEmwXndKSzVyPUKuNVY4PjJizszN
MC-CARMoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrVOFRKSzVyPUKuNlI6PSEQvF2=
KM-H2NXnTeGhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYKwW3gzUUN3ME2yMlI6ODR|IN88US=>
ECC12NGrsNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorGTWM2OD1{LkO3PVQh|ryP
HCE-TMl3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF[x[|VKSzVyPUKuOFQ5QDNizszN
MFM-223NWjGSnhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF65enBKSzVyPUKuOVA5PzFizszN
SW982MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nObmlEPTB;Mj61NVQ5KM7:TR?=
KG-1NYThbHh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7u[m54UUN3ME2yMlg5PzlzIN88US=>
ES4MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTNwME[xNVEh|ryP
SCC-3Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTNwMUC4OFgh|ryP
RH-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TpRWlEPTB;Mz6zPFc1QCEQvF2=
NCI-H748Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXjcYZKSzVyPUOuOFQzPjZizszN
HCC2218NGLBcFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PUTWlEPTB;Mz60Olk{PyEQvF2=
MEG-01NIPWVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjKRphKSzVyPUOuOVk3QCEQvF2=
NB12MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13FbWlEPTB;Mz61PVg5QCEQvF2=
SNB75NHjjV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTNwNkCxNFMh|ryP
KMS-12-PENIfPbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTNwNke3NlMh|ryP
SKM-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTNwN{GzO|Yh|ryP
COLO-320-HSRMlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjH[mxKSzVyPUOuO|U3OzRizszN
NKM-1M2r3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfrbVRKSzVyPUOuO|c{PzhizszN
TE-6NYnJRZIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTNwOUS1OlEh|ryP
D-336MGMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fEO2lEPTB;ND6wNVE3PiEQvF2=
NCI-H1650M3vuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PXSGlEPTB;ND6xOVc6PyEQvF2=
ES3NXnRR4JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTRwM{K4NlQh|ryP
YTM33JbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTjV2xKSzVyPUSuN|U1OjRizszN
ES5NFP0cHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzic5F7UUN3ME20MlQxOjV3IN88US=>
LB647-SCLCMlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYGyc2Q{UUN3ME20MlU3OzB6IN88US=>
HAL-01MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjUTWM2OD12LkW3NFM1KM7:TR?=
LP-1NFfJUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjmfWpNUUN3ME20MlczOzdzIN88US=>
BC-1MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrZRVdlUUN3ME21MlAxPDR5IN88US=>
EB-3MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnzZpNWUUN3ME21MlA{ODRzIN88US=>
GT3TKBNWHObWNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTVwMUe2OlIh|ryP
NCI-H209MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULnU3pFUUN3ME21MlE6OzV{IN88US=>
BT-474NEj5NGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVHxemlkUUN3ME21MlI{OTB{IN88US=>
RKONIfRVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnMWIZKSzVyPUWuNlM1OjJizszN
SIMAMl\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjI[HJKSzVyPUWuN|A4PjVizszN
RLMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7OTWM2OD13LkO3OVQyKM7:TR?=
GCIYM17hUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTVwNEeyN|Yh|ryP
Calu-6MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTVwNkKyJO69VQ>?
ALL-POMlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFewOW1KSzVyPUWuOlM4QTVizszN
ARH-77MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37vU2lEPTB;NT62O|A5PyEQvF2=
A4-FukNWnneHVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlv4TWM2OD14LkC4NVE5KM7:TR?=
NCI-H1581MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3v5bmlEPTB;Nj6yN|g1QSEQvF2=
HUTU-80M3\ScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXwTWM2OD14LkO2PFk4KM7:TR?=
TGWNWnjVpU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TXWmlEPTB;Nj60OVU6OyEQvF2=
SK-N-FINVrROWs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTZwNEW4OVQh|ryP
U-266MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTZwNUG5NlYh|ryP
EM-2MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXv5ZlA{UUN3ME22MlY4ODl7IN88US=>
NMC-G1M1jzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoThTWM2OD14LkexPFk2KM7:TR?=
KASUMI-1NHL5R3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnpTY1KSzVyPU[uPFQ4QDdizszN
NALM-6MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjHd21KSzVyPU[uPFY4PTRizszN
OCI-AML2NI\vfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoSxTWM2OD15LkCwN|I3KM7:TR?=
SHP-77MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;uR41KSzVyPUeuNlI1OyEQvF2=
NOMO-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXnS49PUUN3ME23MlI1OjV2IN88US=>
SK-N-DZM1joXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnETWM2OD15LkexNFg6KM7:TR?=
LB1047-RCCNVvmOIFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILkdJNKSzVyPUeuO|IzOzFizszN
MZ1-PCMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTdwOE[1OVgh|ryP
NB10NHezd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnUdYxKSzVyPUeuPVk2PTZizszN
RL95-2NHfqSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRThwMUC4OFIh|ryP
OMC-1MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFL3cFNKSzVyPUiuOVIyQTFizszN
D-283MEDMon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XWXWlEPTB;OD65NVcyQSEQvF2=
MC116MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRThwOUe5OEDPxE1?
SJSA-1M1n2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXztNldkUUN3ME25MlA6ODlzIN88US=>
JiyoyeP-2003MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHhSnAxUUN3ME25MlI6OzF5IN88US=>
IST-MEL1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;Gblc4UUN3ME25Mlc1OTl6IN88US=>
CTV-1NXnjTnRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7ETWM2OD1zMD6wPVc6KM7:TR?=
NH-12NX;IOlJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTFyLkK0N|Mh|ryP
CA46Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTadIR6UUN3ME2xNE4{PjFizszN
NCI-SNU-1NW\KSoVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTvVo9wUUN3ME2xNE41QTZ7IN88US=>
SCLC-21HMlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;Jc|BFUUN3ME2xNE43PTl4IN88US=>
EC-GI-10MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTFyLkewN|Eh|ryP
SRMk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjvRpVKSzVyPUGxMlAyQDVizszN
NCI-H1648MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrSOoFmUUN3ME2xNU4xQTZ3IN88US=>
TGBC1TKBNEn1SpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfaR5NKSzVyPUGxMlQyODJizszN
EW-11MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3qzNGlEPTB;MUGuOVE5PiEQvF2=
SK-MM-2MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTFzLkiwOlEh|ryP
NCI-H524MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1y4UGlEPTB;MUGuPVgzOiEQvF2=
NOS-1M3LGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXCWHZKSzVyPUGyMlA{PDVizszN
AM-38MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXEfXNKSzVyPUGyMlU3OzNizszN
A498M3XYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXT3RoEzUUN3ME2xNk44ODZ7IN88US=>
KARPAS-422NETLNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvNdFE1UUN3ME2xNk44PDl4IN88US=>
LU-139NVf4WIp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVK0XodvUUN3ME2xNk46ODJ4IN88US=>
COR-L88NIL3S4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjQXZJKSzVyPUGyMlk{QDJizszN
K5M3u4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTF{Lkm0OlIh|ryP
NB13MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfjTIJKSzVyPUGyMlk4QDNizszN
MRK-nu-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvOcoFKSzVyPUGzMlE6PSEQvF2=
MHH-NB-11NVzmToJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHaTWM2OD1zMz6yPVAzKM7:TR?=
KU812M3rIXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7OTWM2OD1zMz62NVI1KM7:TR?=
TE-12M{PteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTF|Lk[5PVQh|ryP
NCI-N87MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTF|LkezOkDPxE1?
EB2Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPUOmZKSzVyPUGzMlg2ODVizszN
DBMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjzTWM2OD1zMz65PFg2KM7:TR?=
697NIW5VGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfBN3NKSzVyPUG0MlQ2OTFizszN
MSTO-211HNEC1bW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlX4TWM2OD1zND63OFQ5KM7:TR?=
JVM-2NGP6eI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTTNXNKSzVyPUG0Mlc4OzVizszN
COLO-824MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXNXnhpUUN3ME2xOE44QTl2IN88US=>
BC-3M2rXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTsTWM2OD1zNT6zPVgh|ryP
BOKUNU\j[|NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTG[GhsUUN3ME2xOU46PjB6IN88US=>
GOTOM1izR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXiR5FtUUN3ME2xOk46PjF5IN88US=>
HCC2157MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXxTWM2OD1zNz60O|U2KM7:TR?=
LS-1034NV2xOYNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLG[nN3UUN3ME2xO{43QDF6IN88US=>
CAL-148NH3JfoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoqxTWM2OD1zNz65O|k3KM7:TR?=
MOLT-4NH[5OpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfENWlKSzVyPUG4MlgzODhizszN
DaudiMm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonPTWM2OD1zOD65NlMyKM7:TR?=
J-RT3-T3-5NHfQfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fwTGlEPTB;MUmuOFA3PiEQvF2=
KMOE-2M2jobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPpNXFKSzVyPUG5MlY1QDJizszN
HL-60NFjGOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXCZlZKSzVyPUKwMlE6PjVizszN
P31-FUJMnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjGb4RKSzVyPUKwMlQ4PTNizszN
IM-9MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVT5eIhWUUN3ME2yNE43OjJ2IN88US=>
HDLM-2M1LBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm[1TWM2OD1{MD64PFIyKM7:TR?=
NCI-H1304Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnCWZVQUUN3ME2yNU4xOzFzIN88US=>
NCI-H345Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHkTWM2OD1{MT6wOlQ{KM7:TR?=
RPMI-6666NV;YTGNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTJzLkO2NFIh|ryP
GR-STM1XEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnJcIw5UUN3ME2yNU41OTdizszN
CHP-126MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnL0TWM2OD1{MT62NVgyKM7:TR?=
EHEBNXHPb5I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;CUo5HUUN3ME2yNU43PzNzIN88US=>
CPC-NMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTJ2LkCyNFEh|ryP
NB1MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTJ2Lk[5N|kh|ryP
LS-123Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTJ2LkmwNVIh|ryP
ST486MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\oTWM2OD1{NT6xNVE{KM7:TR?=
NCI-H1963M{nzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTJ4LkC2NlMh|ryP
U-87-MGM4G4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTJ4Lke2OFQh|ryP
COR-L279MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1r6OWlEPTB;Mk[uO|kzOiEQvF2=
LU-165MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTJ6LkC4OlEh|ryP
COLO-800MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvDVpYxUUN3ME2yPE4zQTV4IN88US=>
ETK-1NF23TotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjJOGZUUUN3ME2yPE4{PDR4IN88US=>
LNCaP-Clone-FGCMl3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;0TWM2OD1{OT65NlgyKM7:TR?=
SIG-M5M2HjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnGVnlpUUN3ME2zNE44QTV{IN88US=>
NB6MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4juS2lEPTB;M{CuPVUxOyEQvF2=
NCI-H2107MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlroTWM2OD1|MT6yN|M5KM7:TR?=
SNU-C1NETGcHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTxZoFKSzVyPUOxMlMyOjZizszN
JARNW[4cZl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPQdmdMUUN3ME2zNU4{Pzl7IN88US=>
L-363M1\NSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDmTWM2OD1|Mj6yNVQ1KM7:TR?=
EW-24M1fyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjVNZRKSzVyPUOyMlM1PzRizszN
NB69M2PEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTN|Lk[0OVQh|ryP
EW-13MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DVPWlEPTB;M{OuPFk3QSEQvF2=
Ramos-2G6-4C10NEHoXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37E[WlEPTB;M{SuNlk6OyEQvF2=
TE-11NEXQc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LmT2lEPTB;M{SuOFgzOiEQvF2=
L-428NELNO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\qdGlEPTB;M{SuO|U{PiEQvF2=
KP-N-YNMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\nfWlEPTB;M{SuPVA2PyEQvF2=
CGTH-W-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jneGlEPTB;M{[uPVA1QCEQvF2=
K-562NFvWOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XjfWlEPTB;M{euNFg3PCEQvF2=
NCI-H1299NWTUW5NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPSRVlKSzVyPUO4MlE3ODNizszN
RCC10RGBNELiZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTN6LkKwPFMh|ryP
NCI-SNU-16MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HZVGlEPTB;M{iuOVY2OyEQvF2=
LC-2-adM4K2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHSXpU1UUN3ME2zPU41OzN5IN88US=>
MHH-PREB-1NXnJeoFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXu2T255UUN3ME2zPU44Ozh6IN88US=>
NCI-H64NGr2XpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTRyLkC5OFgh|ryP
LB996-RCCM3LCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTRyLki3NVYh|ryP
DELNWTlOm9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrJTWM2OD12MT60OFA2KM7:TR?=
MLMAMoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfTTWM2OD12MT63OVk2KM7:TR?=
SBC-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHnNGk2UUN3ME20Nk4yQDB4IN88US=>
MPP-89MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTMTY9tUUN3ME20Nk42QDd3IN88US=>
MV-4-11NH7tU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFywXnFKSzVyPUSyMlkxPjdizszN
EoL-1-MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3y5T2lEPTB;NESuNVU3QCEQvF2=
CW-2MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTR2LkizOFIh|ryP
HTM3;wTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\MUXV6UUN3ME20OU44ODB5IN88US=>
SW954NV[2Z4JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7zcpBKSzVyPUS3MlQyOjhizszN
A3-KAWNVPTeVY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\pTotbUUN3ME20PU45ODZzIN88US=>
TC-YIKMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2D0W2lEPTB;NUCuNFM3OyEQvF2=
SW962MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2m4UmlEPTB;NUSuPFM2PyEQvF2=
KP-N-RT-BM-1NEnk[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LuTmlEPTB;NU[uOlY{QCEQvF2=
NCI-H1395MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\3cHVOUUN3ME21PE45OTd{IN88US=>
RPMI-8402NV3tb|NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLmTWM2OD13OD65OVI3KM7:TR?=
SCHMl;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PHbmlEPTB;NkCuPVY{QCEQvF2=
NCI-H2196NHHL[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTZzLkKzNUDPxE1?
LOXIMVINXzycFIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHSTWM2OD14MT64NlY3KM7:TR?=
TGBC24TKBMkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DQbmlEPTB;NkKuNVQ6OSEQvF2=
SK-MEL-2NEDER4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfVN|FxUUN3ME22N{46QDl{IN88US=>
U-698-MNVTTSo9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTZ6LkW2PFch|ryP
NCI-H1522M{PqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXtTWM2OD14OT6wNFQ4KM7:TR?=
UACC-812NFrEV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTZ7LkWyNFkh|ryP
MHH-CALL-2MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTdyLkC2JO69VQ>?
NB5MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXYSo9ZUUN3ME23NE4{PDZ6IN88US=>
KARPAS-299NHrPeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vhNGlEPTB;N{CuOFQ1PyEQvF2=
NCI-H1694NFnHXotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTxfZFKSzVyPUexMlA{OiEQvF2=
NCI-H82NWXPcHZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLBR5JKSzVyPUexMlk2ODdizszN
SCC-15NFPSbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULwTVJkUUN3ME23Nk4{PCEQvF2=
NCI-H1436NUPhOZBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWW0OlY1UUN3ME23Nk44PDV4IN88US=>
ATN-1NG[1WolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXY[mFXUUN3ME23OE42ODVizszN
RPMI-8866NV72Z2hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2P3e2lEPTB;N{SuO|UxQSEQvF2=
HCC1599MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTd2Lki3N|Ih|ryP
NCI-H1155M{G5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTd2LkmzOlch|ryP
DOHH-2NUC4SJNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYi0PXB1UUN3ME23OE46PTF2IN88US=>
SK-NEP-1NX61W5dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjaT3ZKSzVyPUe1MlA4PTRizszN
HCC1187M13KPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mkj0TWM2OD15Nz62NVIzKM7:TR?=
NCI-H322MNH7BfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\5ZVRGUUN3ME23PE4{PzB7IN88US=>
NCI-H526NVnXWJRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDzTWM2OD15OD61PFc4KM7:TR?=
NCI-H2171NYrnbmRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\uTWM2OD15OT60NVM3KM7:TR?=
COLO-668M17Xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknBTWM2OD16MT61PFg1KM7:TR?=
RS4-11M4XzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjoU2hXUUN3ME24Nk4zPTB3IN88US=>
NCI-H716MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTh{LkmwO|Uh|ryP
LU-134-AMoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfTTWM2OD16Mz6xN|UyKM7:TR?=
RPMI-8226M{fUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTzb|kzUUN3ME24OE4zOTB5IN88US=>
KY821MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moj1TWM2OD17MT62OVUyKM7:TR?=
ECC4NV7P[nhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rHe2lEPTB;OUOuPFI3QSEQvF2=
EW-3M2LyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\BbmNKSzVyPUm0MlkxQDFizszN
NB7M4TTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTsTlI3UUN3ME25OU44Pzh4IN88US=>
NCI-H720Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTl6LkSwOlEh|ryP
NCI-H446NGXx[|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnYWJVmUUN3ME25PU44PTh6IN88US=>
NCI-H889MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTFyND6yOFIh|ryP
EW-22MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\OOmV3UUN3ME2xNFYvOTlizszN
BV-173NH3ueWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjOTWM2OD1zMEiuO|I5KM7:TR?=
WSU-NHLMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXxeY5KSzVyPUGwPU43PzFizszN
MN-60MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXKSXZ2UUN3ME2xNFkvPjlizszN
DG-75Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrvWoVEUUN3ME2xNVMvOzV{IN88US=>
DMS-79MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TveGlEPTB;MUG3MlM5OiEQvF2=
SK-MEL-1NHLuVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{e3[mlEPTB;MUG4MlAxQSEQvF2=
DMS-153M{nwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIj3cINKSzVyPUGyNU44PDVizszN
NCI-H510AM3zpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fZS2lEPTB;MUK3MlMzKM7:TR?=
BE-13M3LvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTF|ND6wOFQh|ryP
KP-N-YSM1\ZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPyV|ZKSzVyPUGzPU44OzZizszN
SUP-T1NEjKb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljiTWM2OD1zNEOuO|A5KM7:TR?=
EW-12MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTF2ND62PVkh|ryP
NB14MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFP2NJNKSzVyPUG0O{4xQDJizszN
MDA-MB-134-VIM3XreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HHbmlEPTB;MUS4MlI3QCEQvF2=
NCI-H1770NHzBOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTF3Nj6yO|kh|ryP
TURM3vjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTF4Nz64O{DPxE1?
NCI-H1417M2j6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofvTWM2OD1zOECuN|MyKM7:TR?=
IMR-5NGL5ToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTF6MT61O|Eh|ryP
NCI-H226MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PtWGlEPTB;MUi4Mlg3PiEQvF2=
NCI-H187MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;QTWM2OD1zOUCuNFY1KM7:TR?=
SF539NHjJUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTF7Mj63Nlgh|ryP
TALL-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfQN4dDUUN3ME2xPVgvOzB2IN88US=>
TE-441-TM1PZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIX4NHVKSzVyPUG5PU44OzlizszN
REHNVrIUpVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTJ|Nj62NlYh|ryP
MS-1NHvYZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rQR2lEPTB;MkO5MlEzOSEQvF2=
THP-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTJ4ND63N|gh|ryP
NCI-H1838NFviZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvzPVdNUUN3ME2yO|EvPDV4IN88US=>
P30-OHKM1jMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTJ6Mz64OFch|ryP
C8166M17MTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTN2NT6zN|gh|ryP

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Measurement of inhibitory activities of MG-132 against 20S proteasome The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.

Cell Assay:

[3]

Cell lines KIM-2, HC11, and ES
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 24, and 48 hours
Method

Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.

Animal Study:

[7]

Animal Models Male mdx (C57BL/10ScSn DMD mdx) mice
Formulation Dissolved in DMSO, and diluted in PBS
Dosages ~10 μg/kg/day
Administration Injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tsubuki S, et al. J Biochem, 1996, 119(3), 572-576.

[2] Fiedler MA, et al. Am J Respir Cell Mol Biol, 1998, 19(2), 259-268.

view more

Chemical Information

Download MG-132 SDF
Molecular Weight (MW) 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 95 mg/mL (199.73 mM)
Ethanol 95 mg/mL (199.73 mM)
Water <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate

Customer Product Validation (9)


Click to enlarge
Rating
Source Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck
Method Immunoprecipitation
Cell Lines MDA-MB-231 cells
Concentrations 10 uM
Incubation Time 6 h
Results SIAH2 destabilizes LATS2 through proteasome. SIAH2-mediated LATS2 degradation was inhibited by proteasomal inhibitor MG132, but not by lysosomal inhibitor BA-1. The half-life of LATS2 was shortened by SIAH2.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck
Method Western blot
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results As RMND5A downregulation resulted in a rapid decrease of protein Exportin-5, this effect was partially abolished by the proteasome inhibitor MG132, indicating that RMND5A protect Exportin-5 protein against proteasome degradation.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck
Method Immunocytochemistry
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results It was surprised to observe that Exportin-5 retention in nucleus when its protein levels were downregulated by RMND5A siRNA or miR-138. The proteasome inhibitor MG132 could recover not only Exportin-5 protein levels but also its normal subcellular localization.

Click to enlarge
Rating
Source EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck
Method Western Blot
Cell Lines MEF cells
Concentrations 30 uM
Incubation Time 6 h
Results Treatment of MEF with proteasome inhibitor MG132 resulted in similar increase of steady state levels of intracellular ATZ in both GFP- and TFEB- transfected Cells.

Click to enlarge
Rating
Source Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck
Method Western Blot
Cell Lines A375, Lu1205 cells
Concentrations 5 uM
Incubation Time 10 h
Results MG132 treatment increased JAK1 steady-state levels, masking the effect of RNF125 depletion and partially blocking deregulated JAK1 expression by ectopically expressed RNF125.

Click to enlarge
Rating
Source Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck
Method Immunoblot analysis
Cell Lines Arabidopsis thaliana
Concentrations 100 uM
Incubation Time 12 h
Results These rates of loss were markedly slower in the lrb1-1 lrb2-1 background. Importantly, phyB breakdown was also substantially attenuated upon exposing wild-type seedlings to the proteasome inhibitor MG132, thus implicating the 26S proteasome in particular. MG132 treatment also slightly stabilized phyB levels in lrb1-1 lrb2-1 seedlings, implying that other factors besides LRB1 and LRB2 might also direct phyB breakdown.

Click to enlarge
Rating
Source Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck
Method Immunofluorescence
Cell Lines γ-H2AX-stained cells
Concentrations 100 uM
Incubation Time 3 h
Results G2 cell cycle arrest usually reflects the formation of genomic damage in the preceding S-phase, which activates checkpoint response upon the entry of cells into G2 phase. Furthermore, MG132-treated cells also had larger amounts of γ-H2AX, as evidenced by the increased staining in individual nuclei .

Click to enlarge
Rating
Source FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck
Method Western Blot
Cell Lines Hela cells
Concentrations
Incubation Time 12 h
Results When GSK-3 (Ser9) degradation was blocked by proteasome inhibitor (MG132), the increased amount of phosphorylated GSK-3 (Ser9) in responding to NOK was more clearly observed in the HeLa-NOK-HA cells (Fig. C).

Click to enlarge
Rating
Source 2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck
Method Western blot
Cell Lines NIH3T3 cells
Concentrations 25 μM
Incubation Time 1-4 h
Results By adding MG132, a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment.

Product Use Citation (40)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • PI-1840

    PI-1840 is a reversible and selective chymotrypsin-like (CT-L) inhibitor with IC50 of 27 nM with little effects on the other two major proteasome proteolytic activities, trypsin-like (T-L) and postglutamyl-peptide-hydrolysis-like (PGPH-L).

  • SB-3CT

    SB-3CT is an effective and selective gelatinase inhibitor with Ki of 13.9 nM and 600 nM for MMP-2 and MMP-9, respectively.

  • Leupeptin Hemisulfate

    Leupeptin Hemisulfate is a reversible inhibitor of serine and cysteine proteases.

  • Bortezomib (PS-341)

    Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

Recently Viewed Items

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
Contact Us